Diet, exercise, therapy and drugs can help obese people get healthier. But weight-loss surgery does a better job of getting rid of extra pounds and treating Type 2 diabetes, a new review of past studies shows.
The studies only followed people for two years. So it's possible the results would look different further down the line, the authors write.
So-called bariatric surgery, like gastric bypass or gastric banding, reduces the size of the stomach so patients can only eat small amounts of food.
Many doctors have noted the dramatic weight loss that often results. But it wasn't obvious how surgery stacks up against traditional diet and exercise strategies.
The new review included 11 studies. Each study randomly chose some obese people to have surgery and others to make diet or lifestyle changes instead, for instance. Together those studies included close to 800 people.
Participants in the bariatric surgery groups lost an average of 57 more pounds than those in the non-surgery groups. Average weight loss ranged from 45 to 100 pounds among those who had surgery.
More people who had Type 2 diabetes saw their blood sugar levels fall into the normal range after surgery than after a different intervention.
"Although they try to look at a range of medical conditions, in reality the real importance is the effect of weight loss on diabetes and the relative effectiveness of non-surgical versus surgical approaches," said Dr. Paul O'Brien.
O'Brien is an obesity specialist who pioneered the Lap-Band procedure in Australia in 1994. He founded the Centre for Obesity Research and Education at Monash University in Melbourne and was not involved in the new review. article research by
http://naturalcure.productzone.net/
"The clear and consistent message is the bariatric surgical procedures achieve a much better outcome," O'Brien said.
Bariatric surgery will certainly help obese people with diabetes better control the disease and may put it into remission entirely, he said.
"Given that there are probably in excess of 300 million people across the world with Type 2 diabetes and maybe half of these are obese, this opens up huge possibilities for better health," O'Brien said.
But two years isn't really enough time to judge the results. And the analysis included small numbers of studies and patients, Viktoria L. Gloy from University Hospital Basel in Switzerland and colleagues note in the journal BMJ.
Longer-term studies, cost-effectiveness studies and comparisons between different surgeries are still missing, O'Brien said read for more details visit my web page http://causebadbreath.pagelanding.net/
.
The authors did not respond to a request for comment before deadline.
Surgery is typically recommended for people with a body mass index - a measure of weight in relation to height - of at least 40, or at least 35 if they also have co-occurring health problems such as diabetes or severe sleep apnea.
"I think an important point to consider is that most of the studies suggest that bariatric surgery combined with intensive lifestyle management is superior to lifestyle management alone," said Dr. Richdeep Gill. He is a general surgeon at the University of Alberta in Canada.
Generally people who undergo weight-loss surgery must try lifestyle changes like diet and exercise first before going under the knife. So it may not be an either/or choice for most obese people.
Gill, for more information about health http://bodyodor.campaignsites.net/
who studies bariatric surgery, was not involved in the review.
Patients need to be informed about the risks of surgery, he said.
According to the National Institutes of Health, gastric bypass surgery carries risks of allergic reactions to anesthesia, blood clots, breathing problems, heart attack, stroke or infection.
In the review, 15 percent of people in the surgery groups had anemia from low iron levels post-surgery and 8 percent needed a second operation.
It's impossible to say how serious those additional surgeries were. But second surgeries are always more difficult than the first, Gill said.
Post-surgery, patients must stick to a special diet for life and often have to avoid some common medications like aspirin and other non-steroidal anti-inflammatory drugs.
"Tackling obesity is a challenging issue, and the patient needs to be committed to their own management strategy," Gill said. Only then, with consultation of a multidisciplinary care team, will surgery be considered as an option.
Friday, December 20, 2013
Wild Blueberries Prevent Diabetes: Study
Wild blueberry fans, rejoice. New research shows that diets rich in the sweet, nutritious fruit can help stave off diabetes, as well as heart disease.
The study, published in the journal Applied Physiology, Nutrition, and Metabolism, eating the equivalent of two cups a day of wild blueberries can improve or even prevent metabolic syndrome (MetS) — a group of high-risk conditions including obesity, high blood pressure, inflammation, glucose intolerance, and insulin resistance that increase the odds of developing cardiovascular problems and diabetes.
Klimis-Zacas, M.D., for more information about health http://darwinsmith.mobilewebpage.net/
a professor of clinical nutrition at the University of Maine, noted blueberries are a rich source of phytochemicals called polyphenols, which have been reported by a growing number of studies to offer a variety of protective health benefits. The new findings, based on research involving laboratory rats, add to that evidence and suggest blueberries might even reduce the need for medication. "MetS affects an estimated 37 percent of adults in the U.S.," said Klimis-Zacas. read for more details visit my web page http://whatiscandida.eventpages.org/
"We have previously documented the cardiovascular benefits of a polyphenol-rich wild blueberry in a rat model with impaired vascular health and high blood pressure. Our new findings show that these benefits extend to the obese Zucker rat, a widely used model resembling human MetS." According to the study, wild blueberry consumption — about two cups per day — for 8 weeks was shown to regulate and improve the blood flow and blood pressure in rats with metabolic syndrome. "Our recent findings reported elsewhere, documented that wild blueberries reduce chronic inflammation and improve the abnormal [cholesterol levels] and gene expression associated with the MetS," Klimis-Zacas said. He added that the new study shows "regular long-term wild blueberry diets may also help improve pathologies associated with the MetS."
a professor of clinical nutrition at the University of Maine, noted blueberries are a rich source of phytochemicals called polyphenols, which have been reported by a growing number of studies to offer a variety of protective health benefits. The new findings, based on research involving laboratory rats, add to that evidence and suggest blueberries might even reduce the need for medication. "MetS affects an estimated 37 percent of adults in the U.S.," said Klimis-Zacas. read for more details visit my web page http://whatiscandida.eventpages.org/
"We have previously documented the cardiovascular benefits of a polyphenol-rich wild blueberry in a rat model with impaired vascular health and high blood pressure. Our new findings show that these benefits extend to the obese Zucker rat, a widely used model resembling human MetS." According to the study, wild blueberry consumption — about two cups per day — for 8 weeks was shown to regulate and improve the blood flow and blood pressure in rats with metabolic syndrome. "Our recent findings reported elsewhere, documented that wild blueberries reduce chronic inflammation and improve the abnormal [cholesterol levels] and gene expression associated with the MetS," Klimis-Zacas said. He added that the new study shows "regular long-term wild blueberry diets may also help improve pathologies associated with the MetS."
Acidic Foods Found to Increase Diabetes Risk
To avoid developing type 2 diabetes, you may have been told to watch your calories and kick up your activity level. Now researchers say there's something else you might consider: your so-called dietary acid load.
A diet heavy in animal products and other acidic foods can cause an acid load in the body, resulting in health complications. This includes reduced insulin sensitivity, which can lead to type 2 diabetes, according to the new study.
"We have demonstrated for the first time in a large prospective study that dietary acid load was positively associated with type 2 diabetes risk, independently of other known risk factors for diabetes," the researchers said. article research by http://cellulitereview.willgetmarried.com/
"Our results need to be validated in other populations, and may lead to promotion of diets with a low acid load for the prevention of diabetes." The term animal products refers to meat, eggs and dairy. Greater consumption of fruits and vegetables is believed to lead to a lower acid load, the researchers said. The study included more than 66,000 women in Europe who were followed for more than 14 years. During that time, nearly 1,400 of the women were diagnosed with type 2 diabetes. for more information about health
http://kyleleon.justgotmarried.net/
Those with diets highest in acidic foods were 56 percent more likely to develop diabetes than those with diets lowest in acidic foods, according to the study, which was published recently in the journal Diabetologia. This link between a highly acidic diet and increased risk of diabetes remained even after the researchers adjusted for dietary patterns, meat consumption and intake of fruit, vegetables, coffee and sweetened beverages.
The study did not, however, prove that a highly acidic diet actually causes diabetes. "A diet rich in animal protein may favor net acid intake, while most fruits and vegetables form alkaline precursors that neutralize the acidity," wrote Dr. Guy Fagherazzi and Dr. Francoise Clavel-Chapelon, of the Center for Research in Epidemiology and Population Health at INSERM, in Paris. "Contrary to what is generally believed, most fruits -- such as peaches, apples, pears, bananas and even lemons and oranges -- actually reduce dietary acid load once the body has processed them."
"Our results need to be validated in other populations, and may lead to promotion of diets with a low acid load for the prevention of diabetes." The term animal products refers to meat, eggs and dairy. Greater consumption of fruits and vegetables is believed to lead to a lower acid load, the researchers said. The study included more than 66,000 women in Europe who were followed for more than 14 years. During that time, nearly 1,400 of the women were diagnosed with type 2 diabetes. for more information about health
http://kyleleon.justgotmarried.net/
Those with diets highest in acidic foods were 56 percent more likely to develop diabetes than those with diets lowest in acidic foods, according to the study, which was published recently in the journal Diabetologia. This link between a highly acidic diet and increased risk of diabetes remained even after the researchers adjusted for dietary patterns, meat consumption and intake of fruit, vegetables, coffee and sweetened beverages.
The study did not, however, prove that a highly acidic diet actually causes diabetes. "A diet rich in animal protein may favor net acid intake, while most fruits and vegetables form alkaline precursors that neutralize the acidity," wrote Dr. Guy Fagherazzi and Dr. Francoise Clavel-Chapelon, of the Center for Research in Epidemiology and Population Health at INSERM, in Paris. "Contrary to what is generally believed, most fruits -- such as peaches, apples, pears, bananas and even lemons and oranges -- actually reduce dietary acid load once the body has processed them."
Breathalyzer Tracks Blood Sugar Without Needles
The world's first functional breathalyzer for diabetes has been created by scientists who say the new hand-held device can be used to track blood sugar levels, offering a needle-free alternative to pin pricks now used to draw blood to test for glucose multiple times a day. for more information about health http://fatloss.photographist.me/
The advance, unveiled at a meeting of the American Association of Pharmaceutical Scientists in San Antonio this week, uses nanotechnology to detect acetone in the breath of diabetics — a chemical that has been shown to correlate with blood-glucose levels. "Breathalyzers are a growing field of study because of their potential to have a significant positive impact on patients' quality of life and compliance with diabetes monitoring," said Ronny Priefer, of Western New England University, who created the new device. for more details go to the link http://customizedfatloss.isourchurch.com/
"What makes our technology different is that it only accounts for acetone and doesn't react with other components in the breath." Priefer noted the current device is the size of a book, but his team is working with an engineering team to make it as small as a typical alcohol-detecting breathalyzer. Priefer said he will use two Western New England University clinics to test the new device on patients over the next two years, by comparing readings from the breathalyzer, finger pricking, and actual glucose levels from drawn blood. Diabetes, which affects nearly 350 million people worldwide, is an autoimmune disease that prevents the cellular uptake of sugar from the blood and often requires continuous blood-glucose monitoring using needle sticks to draw blood.
The advance, unveiled at a meeting of the American Association of Pharmaceutical Scientists in San Antonio this week, uses nanotechnology to detect acetone in the breath of diabetics — a chemical that has been shown to correlate with blood-glucose levels. "Breathalyzers are a growing field of study because of their potential to have a significant positive impact on patients' quality of life and compliance with diabetes monitoring," said Ronny Priefer, of Western New England University, who created the new device. for more details go to the link http://customizedfatloss.isourchurch.com/
"What makes our technology different is that it only accounts for acetone and doesn't react with other components in the breath." Priefer noted the current device is the size of a book, but his team is working with an engineering team to make it as small as a typical alcohol-detecting breathalyzer. Priefer said he will use two Western New England University clinics to test the new device on patients over the next two years, by comparing readings from the breathalyzer, finger pricking, and actual glucose levels from drawn blood. Diabetes, which affects nearly 350 million people worldwide, is an autoimmune disease that prevents the cellular uptake of sugar from the blood and often requires continuous blood-glucose monitoring using needle sticks to draw blood.
Diabetes War 'Being Lost' as Cases Hit Record 382 Million
The world is losing the battle against
diabetes as the number of people estimated to be living with the
disease soars to a new record of 382 million this year, medical experts
said on Thursday. article research by http://newbodyreview.theclever.me/
The vast majority have type 2 diabetes - the kind linked to
obesity and lack of exercise - and the epidemic is spreading as more
people in the developing world adopt Western, urban lifestyles.
The latest estimate from the International Diabetes Federation is equivalent to a global prevalence rate of 8.4 percent of the adult population and compares to 371 million cases in 2012.
By 2035, the organization predicts the number of cases will have soared by 55 percent to 592 million.
"The battle to protect people from diabetes and its disabling, life-threatening complications is being lost," the federation said in the sixth edition of its Diabetes Atlas, noting that deaths from the disease were now running at 5.1 million a year or one every six seconds. for more information about health http://sixpacksabs.thenerd.me/
People with diabetes have inadequate blood sugar control, which can lead to a range of dangerous complications, including damage to the eyes, kidneys and heart. If left untreated, it can result in premature death.
"Year after year, the figures seem to be getting worse," said David Whiting, an epidemiologist and public health specialist at the federation. "All around the world we are seeing increasing numbers of people developing diabetes."
He said that a strategy involving all parts of society was needed to improve diets and promote healthier lifestyles.
The federation calculates diabetes already accounts for annual healthcare spending of $548 billion and this is likely to rise to $627 billion by 2035.
Worryingly, an estimated 175 million of diabetes cases are as yet undiagnosed, so a huge number of people are progressing towards complications unawares. Most of them live in low- and middle-income countries with far less access to medical care than in the United States and Europe.
The country with the most diabetics overall is China, where the case load is expected to rise to 142.7 million in 2035 from 98.4 million at present.
But the highest prevalence rates are to be found in the Western Pacific, where more than a third of adults in Tokelau, Micronesia and the Marshall Islands are already living with the disease.
Pharmaceutical companies have developed a range of medicines over
the years to counter diabetes but many patients still struggle to
control their condition adequately, leading to a continuing hunt for
improved treatments.
3 Cups of Coffee Daily Prevents Diabetes:
Coffee drinkers, rejoice. Drinking at least three cups of coffee a day may decrease your risk of developing Type 2 diabetes, according to the latest research spotlighting the health benefits of the noble caffeine bean.
ALERT: 5 Signs You’ll Get Alzheimer’s Disease
The findings, published by the Institute for Scientific Information on Coffee, are based a series of studies published in the past year compiled by the World Congress on Prevention of Diabetes. http://calories.blooming.me/
Among the key research findings: Epidemiological evidence shows drinking three to four cups of coffee per day is associated with an approximate 25 percent lower risk of developing Type 2 diabetes, compared to consuming none or less than two cups per day. http://dietfoods.likeapro.me/
Research suggests with each additional cup of coffee consumed daily, drinkers reduce their relative risk of developing diabetes by 7-8 percent. Caffeine is unlikely to be responsible for the protective effects of coffee, with one study finding both caffeinated and decaffeinated coffee are associated with a lower risk of Type 2 diabetes One study found regular but not decaffeinated coffee was much more protective against diabetes in women of all ethnic groups than in men. http://venusfactor.thecrazy.me/
The report also noted some research suggests the caffeine in coffee stimulates metabolism and increases energy expenditure and may play a key role by influencing the blood sugar in the body. In addition, some scientific evidence indicates coffee contains components that may improve insulin sensitivity by modulating inflammation, affecting hormones, and reducing iron stores.
Among the key research findings: Epidemiological evidence shows drinking three to four cups of coffee per day is associated with an approximate 25 percent lower risk of developing Type 2 diabetes, compared to consuming none or less than two cups per day. http://dietfoods.likeapro.me/
Research suggests with each additional cup of coffee consumed daily, drinkers reduce their relative risk of developing diabetes by 7-8 percent. Caffeine is unlikely to be responsible for the protective effects of coffee, with one study finding both caffeinated and decaffeinated coffee are associated with a lower risk of Type 2 diabetes One study found regular but not decaffeinated coffee was much more protective against diabetes in women of all ethnic groups than in men. http://venusfactor.thecrazy.me/
The report also noted some research suggests the caffeine in coffee stimulates metabolism and increases energy expenditure and may play a key role by influencing the blood sugar in the body. In addition, some scientific evidence indicates coffee contains components that may improve insulin sensitivity by modulating inflammation, affecting hormones, and reducing iron stores.
Safety Restrictions Lifted on Diabetes Drug Avandia
The Food and Drug Administration is lifting severe safety restrictions on the former blockbuster diabetes pill Avandia, citing recent data suggesting that the much-debated medication does not increase the risk of heart attack.
The repeal means patients will no longer have to enroll in a special registry to be eligible to receive the drug. Additionally, the drug will be available at most pharmacies, whereas it was previously limited to certain registered pharmacies. Those safety restrictions and others were put in place in 2010, severely curbing U.S. prescriptions for the GlaxoSmithKline drug.
Monday's ruling is a belated victory for the British drugmaker, which has spent more than a half-decade defending the safety of Avandia, once the best-selling diabetes drug in the world. Sales began plummeting in 2007 after researchers first raised questions about possible links to heart attacks article research by http://www.articlesempire.com/article.php?id=20693
After three years of debate, the FDA limited access to the drug in 2010. But FDA regulators said Monday a more recent analysis of a key Avandia study shows that the drug's heart risks are no greater than other diabetes drugs. "Given these new results, our level of concern is considerably reduced," said FDA drug center director Dr. Janet Woodcock, in a statement. The announcement also represents a vindication of sorts for FDA leadership, including Woodcock, who only agreed to put restrictions on the pill after years of pressure from outside researchers, safety advocates and several members of Congress. Dr. Steven Nissen of the Cleveland Clinic, whose research first raised concerns about Avandia, said the announcement "is about the FDA's effort to save face." "This is about appearances, not changing medical practice," said Nissen, who chairs the Cleveland Clinic's department of cardiology. read for more details visit my web page
http://articles.al.lv/article.php?id=246628
"A single reanalysis of a trial does not exonerate a drug where all the other data point to increased cardiovascular risks." Nissen said he doesn't expect doctors to return to prescribing the drug, considering how many newer diabetes drugs are now available. Nissen drew attention to Avandia's safety in a 2007 study pooling thousands of reports of heart attack and stroke from dozens of unrelated studies involving the drug. His so-called meta-analysis combined 42 studies and showed a higher risk of heart attack among patients taking Avandia compared to other diabetes drugs.
The FDA eventually agreed to restrict use of the drug, while noting the shortcomings of the analysis that first raised the concern. FDA policy generally holds that mixing data from multiple studies can lead to misleading trends and conclusions. That focused the agency's attention on a study known as RECORD, the only trial to specifically compare heart attack rates in patients taking Avandia versus other standard drug treatments for diabetics. Under instructions from the FDA,
Glaxo hired Duke University to reanalyze the RECORD study, reviewing each report of heart attack or stroke at a patient-by-patient level. Duke's findings, released last year, matched Glaxo's initial conclusion on the study: Avandia did not appear to increase the risk of heart attack compared to standard treatments. Last June a panel of outside experts voted to recommend easing the safety restrictions on Avandia. The FDA is not required to follow the guidance of those experts, though it often does.
A spokeswoman for London-based Glaxo said the company will work with the FDA to revise the drug's labeling and remove current access restrictions. The company has previously stated it has no plans to resume advertising of the drug. In 2012 Glaxo pleaded guilty to failing to report safety problems with Avandia to government officials over a seven-year period. The guilty plea was part of a larger $3 billion settlement with the Department of Justice for various criminal and civil violations involving 10 of the company's drugs.
After three years of debate, the FDA limited access to the drug in 2010. But FDA regulators said Monday a more recent analysis of a key Avandia study shows that the drug's heart risks are no greater than other diabetes drugs. "Given these new results, our level of concern is considerably reduced," said FDA drug center director Dr. Janet Woodcock, in a statement. The announcement also represents a vindication of sorts for FDA leadership, including Woodcock, who only agreed to put restrictions on the pill after years of pressure from outside researchers, safety advocates and several members of Congress. Dr. Steven Nissen of the Cleveland Clinic, whose research first raised concerns about Avandia, said the announcement "is about the FDA's effort to save face." "This is about appearances, not changing medical practice," said Nissen, who chairs the Cleveland Clinic's department of cardiology. read for more details visit my web page
http://articles.al.lv/article.php?id=246628
"A single reanalysis of a trial does not exonerate a drug where all the other data point to increased cardiovascular risks." Nissen said he doesn't expect doctors to return to prescribing the drug, considering how many newer diabetes drugs are now available. Nissen drew attention to Avandia's safety in a 2007 study pooling thousands of reports of heart attack and stroke from dozens of unrelated studies involving the drug. His so-called meta-analysis combined 42 studies and showed a higher risk of heart attack among patients taking Avandia compared to other diabetes drugs.
The FDA eventually agreed to restrict use of the drug, while noting the shortcomings of the analysis that first raised the concern. FDA policy generally holds that mixing data from multiple studies can lead to misleading trends and conclusions. That focused the agency's attention on a study known as RECORD, the only trial to specifically compare heart attack rates in patients taking Avandia versus other standard drug treatments for diabetics. Under instructions from the FDA,
Glaxo hired Duke University to reanalyze the RECORD study, reviewing each report of heart attack or stroke at a patient-by-patient level. Duke's findings, released last year, matched Glaxo's initial conclusion on the study: Avandia did not appear to increase the risk of heart attack compared to standard treatments. Last June a panel of outside experts voted to recommend easing the safety restrictions on Avandia. The FDA is not required to follow the guidance of those experts, though it often does.
A spokeswoman for London-based Glaxo said the company will work with the FDA to revise the drug's labeling and remove current access restrictions. The company has previously stated it has no plans to resume advertising of the drug. In 2012 Glaxo pleaded guilty to failing to report safety problems with Avandia to government officials over a seven-year period. The guilty plea was part of a larger $3 billion settlement with the Department of Justice for various criminal and civil violations involving 10 of the company's drugs.
New Diabetes Pill Would Replace Injections
Novo Nordisk is about to barrage a mid-stage analytic abstraction with a book adaptation of a alleged GLP-1 anesthetic as it accomplish up the coursing for diabetes pills that can alter injections.The Phase II balloon may alpha as aboriginal as abutting anniversary and will absorb about 600 patients, Chief Science Officer Mads Krogsgaard Thomsen said on Thursday.Editor's Note: Knowing these 5 cancer-causing signs is acute to actual cancer-free for life "It is a anniversary because this is not incremental innovation, it's confusing innovation," he told Reuters in an account during a appointment to London. Results of the abstraction are accepted in about a year's time. article research by http://memoto.es/article.php?id=71651
The Danish aggregation is already the world's better supplier of diabetes medicines, which accommodate its accepted GLP-1 artefact Victoza. Like its top-selling insulins, Victoza is currently delivered application a pen bang device.An articulate bolus adaptation would mark a step-change in analysis by authoritative analysis far added convenient, aperture up a above new bazaar at a time back cases of diabetes are aerial worldwide.A absolute of 382 actor bodies are now estimated to be active with the disease. for more information about health http://www.article-galaxy.com/article.php?id=22241
The all-inclusive majority accept blazon 2 diabetes, the affectionate affiliated to blubber and abridgement of exercise.Sales of diabetes drugs were account $42.4 billion common in 2012, according to healthcare advice aggregation IMS Health.Glucagon-like peptide-1 (GLP-1) drugs assignment by aesthetic the absolution of insulin back claret amoroso levels become too low.Making an articulate anatomy of such drugs is far from simple and a key hurdle is to ensure that the anesthetic is abundantly captivated in the body.Thomsen said the abstruse challenges meant there ability be setbacks in the development affairs but he was more optimistic that bearing an able GLP-1 bolus was feasible.
"The abstracts we accept so far suggests we can do it," he said, abacus that Novo was able-bodied advanced of rivals in the field.The 600-patient balloon will analyze the new once-daily GLP-1 bolus adjoin a account bang of a GLP-1 medicine, accepted as semaglutide, that Novo currently has in Phase III trials.If all goes well, Novo believes the GLP-1 bolus could hit the bazaar in about bristles or six years time.Novo is additionally alive on an articulate adaptation of insulin but that is at an beforehand stage, with a accommodation on advanced into Phase II testing still about a year away.
The Danish aggregation is already the world's better supplier of diabetes medicines, which accommodate its accepted GLP-1 artefact Victoza. Like its top-selling insulins, Victoza is currently delivered application a pen bang device.An articulate bolus adaptation would mark a step-change in analysis by authoritative analysis far added convenient, aperture up a above new bazaar at a time back cases of diabetes are aerial worldwide.A absolute of 382 actor bodies are now estimated to be active with the disease. for more information about health http://www.article-galaxy.com/article.php?id=22241
"The abstracts we accept so far suggests we can do it," he said, abacus that Novo was able-bodied advanced of rivals in the field.The 600-patient balloon will analyze the new once-daily GLP-1 bolus adjoin a account bang of a GLP-1 medicine, accepted as semaglutide, that Novo currently has in Phase III trials.If all goes well, Novo believes the GLP-1 bolus could hit the bazaar in about bristles or six years time.Novo is additionally alive on an articulate adaptation of insulin but that is at an beforehand stage, with a accommodation on advanced into Phase II testing still about a year away.
Long-Acting Insulin Shows Promise Against Diabetes
An improved version of Sanofi's diabetes drug Lantus is better than the old one at controlling blood sugar levels and comes with fewer hypoglycemic events, new late-stage trial data showed on Tuesday.
The treatment is one of several drugs Sanofi is betting on to defend its No.2 spot on the world's $42 billion diabetes market as its superstar product Lantus, the world's most prescribed insulin, will lose patent protection by 2015. article research by http://www.1500dollarwebsite.com/article.php?id=352580
The long-acting insulin, known as U300, requires less frequent or lower dosing than Lantus and offers a more consistent insulin release. It is similar to Novo Nordisk's Tresiba (degludec), also in development. Analysts expect Sanofi to seek regulatory approval for U300 in the United States and Europe next year and for the drug to reach global sales of $872 million by 2017, according to forecasts compiled by Thomson Reuters Cortellis. The detailed Phase III results unveiled at the World Diabetes Congress in Melbourne showed U300 was better than Lantus at controlling blood sugar lows at night, a common side effect in diabetics treated with insulin. read for more details visit my web page http://konkanmail.com/article/article.php?id=341212
The drug also lowered the incidence of hypoglycemic events at any time of the day across the six-month study period. U300 met its goal in three other Phase III clinical trials, showing similar blood sugar level control as Lantus in patients with type 2 diabetes not previously treated with insulin and uncontrolled on oral medication, as well as in patients with type 1 diabetes already treated with insulin. Lantus, also known as insulin glargine, was developed in the 1990s and is currently Sanofi's top-selling drug. It reaped around 5 billion euros ($6.78 billion) in revenue last year.
Sanofi needs a successor for the drug and is also developing a pen-shaped device, known as LixiLan, that combines Lantus with Lyxumia, another diabetes treatment belonging to a class of drugs known as GLP-1 analogues. The successful launch of both U300 and LixiLan could strengthen Sanofi against rival drugs such as Novo Nordisk's Tresiba (degludec) and IDegLira, a combination of Tresiba and Victoza. Novo Nordisk, the global leader in diabetes, faced a setback earlier this year when the U.S. Food and Drug Administration asked for further clinical studies for Tresiba, delaying its potential launch on the world's largest pharmaceutical market until 2017 at the earliest.
The long-acting insulin, known as U300, requires less frequent or lower dosing than Lantus and offers a more consistent insulin release. It is similar to Novo Nordisk's Tresiba (degludec), also in development. Analysts expect Sanofi to seek regulatory approval for U300 in the United States and Europe next year and for the drug to reach global sales of $872 million by 2017, according to forecasts compiled by Thomson Reuters Cortellis. The detailed Phase III results unveiled at the World Diabetes Congress in Melbourne showed U300 was better than Lantus at controlling blood sugar lows at night, a common side effect in diabetics treated with insulin. read for more details visit my web page http://konkanmail.com/article/article.php?id=341212
The drug also lowered the incidence of hypoglycemic events at any time of the day across the six-month study period. U300 met its goal in three other Phase III clinical trials, showing similar blood sugar level control as Lantus in patients with type 2 diabetes not previously treated with insulin and uncontrolled on oral medication, as well as in patients with type 1 diabetes already treated with insulin. Lantus, also known as insulin glargine, was developed in the 1990s and is currently Sanofi's top-selling drug. It reaped around 5 billion euros ($6.78 billion) in revenue last year.
Sanofi needs a successor for the drug and is also developing a pen-shaped device, known as LixiLan, that combines Lantus with Lyxumia, another diabetes treatment belonging to a class of drugs known as GLP-1 analogues. The successful launch of both U300 and LixiLan could strengthen Sanofi against rival drugs such as Novo Nordisk's Tresiba (degludec) and IDegLira, a combination of Tresiba and Victoza. Novo Nordisk, the global leader in diabetes, faced a setback earlier this year when the U.S. Food and Drug Administration asked for further clinical studies for Tresiba, delaying its potential launch on the world's largest pharmaceutical market until 2017 at the earliest.
Vitamin D Eases Diabetes Pain: Study
Vitamin D has been shown to ease pain in women with Type 2 diabetes and depression.
According to new study conducted at Loyola University Chicago and presented recently a campus research conference, a significant number of volunteers given weekly vitamin D2 supplementation (50,000 IUs) for six months reported a lessening of pain and their symptoms of depression.
At the start of the study, 61 percent of the women reported shooting or burning pain in their legs and feet (neuropathic pain) and 74 percent reported numbness and tingling in their hands, fingers, and legs (sensory pain). After three to six months of receiving the supplements, article research by
http://partydressshops.com/you-should-not-abandon-active-recreation-outdoors/
the patients reported a significant decrease in neuropathic and sensory pain.
"Pain is a common and often serious problem for women with Type 2 diabetes and depression," said lead researcher Todd Doyle, M.D., with the Loyola Department of Psychiatry & Behavioral Neurosciences. "While further research is needed, D2 supplementation is a promising treatment for both pain and depression in Type 2 diabetes."
Type 2 diabetes is associated with depression and pain, but no prior studies have evaluated the use of vitamin D supplementation as a treatment, for more information about health
http://plooshy.com/2013/12/19/the-ratio-of-fats-proteins-and-carbohydrates/
Dr. Doyle said. Researchers now plan to study how the vitamin works to ease pain and depression, using funding from the National Institutes of Health. "Vitamin D has widespread benefits for our health and certain chronic diseases such as Type 2 diabetes," said Sue Penckofer, a study co-author and professor at the Loyola University Chicago Marcella Niehoff School of Nursing. "This NIH grant will allow us to shed greater light on understanding the role that this nutrient plays in managing the health of women with diabetes."
http://partydressshops.com/you-should-not-abandon-active-recreation-outdoors/
http://plooshy.com/2013/12/19/the-ratio-of-fats-proteins-and-carbohydrates/
Dr. Doyle said. Researchers now plan to study how the vitamin works to ease pain and depression, using funding from the National Institutes of Health. "Vitamin D has widespread benefits for our health and certain chronic diseases such as Type 2 diabetes," said Sue Penckofer, a study co-author and professor at the Loyola University Chicago Marcella Niehoff School of Nursing. "This NIH grant will allow us to shed greater light on understanding the role that this nutrient plays in managing the health of women with diabetes."
Depression Worsens Diabetes Complications: Study
Even mild bouts of depression may worsen the health complications that often go along with type 2 diabetes, according to a new study.
Canadian researchers followed more than 1,000 patients for five years and found those who experienced multiple episodes of low-level depression were nearly three times more likely than those without depression to have greater disability, such as reduced mobility, poor self care and worse quality of life.
"Minor depression is a form of chronic stress," said Dr. Norbert Schmitz, associate professor of psychiatry at McGill University's Douglas Mental Health University Institute in Montreal, who led the study.
"Patients may not be able to follow treatment guidelines or they may have problems with diet, which in turn results in an increased risk of poor functioning," he said.
Diabetes can increase the risk of heart disease, nerve damage, kidney failure and blindness. article research by https://www.goodreads.com/story/show/354140-yoga-for-pregnant-women
The disease affects 25.8 million people in the U.S. and that number is expected to rise dramatically during the next 20 years, according to the Centers for Disease Control and Prevention. Type 2 diabetes is often associated with obesity, but the elderly are also at high risk, with an estimated 27 percent of the over-65 population suffering from the disease. Past research has found that nearly one-fifth of type-2 diabetics in the U.S. experience major depression, which is almost twice the rate seen in the general population. Some studies also link the combination of type 2 diabetes and depression with difficulty managing blood sugar levels and other health complications as well as increased risk of death.
read for more details visit my web page http://www.dailystrength.org/people/3658851/journal/8578893
Most research to date has focused on the role of major depression in poor health outcomes for diabetes patients, but Schmitz and his colleagues wanted to know if mild depression symptoms carried the same risks. For their study, published in Diabetes Care, the researchers followed 1,064 adults, aged 18 to 80 years old, from the larger Montreal Diabetes and Well Being Study for five years. The participants received a battery of surveys that assessed symptoms of depression, measures of disability, quality of life, diabetes-related health complications, social background, exercise and medical and psychiatric history, particularly related to treatment for depression. here is another about link http://www.kiwibox.com/camillafrank/blog/entry/112211095/you-should-not-abandon-active-recreation-outdoors/?pPage=0
The study team defined depression by a score based on symptoms experienced over a period of two weeks. While major depression would require at least five out of nine symptoms - such as appetite changes, fatigue and suicidal thinking - persisting over that time, mild depression would constitute fewer than five symptoms experienced at least once over the previous two weeks. The researchers also looked at health-related quality of life, based on the individuals' own perceptions of how burdensome their health problems were, and translated into a number of "unhealthy days" the person reported over the past month. They found that as the number of episodes of mild depression increased, the risk of impaired health and quality of life grew as well. For participants with one minor depression episode, the rate of poor functioning in daily activities such as work,
domestic responsibilities and self-care was 50 percent higher compared to those who had no depression. For patients with four or more bouts of mild depression, the risk of poor functioning was almost 300 percent greater and the risk of impaired health-related quality of life was nearly 250 percent greater than for those without depression. Schmitz told Reuters Health the study points to the need for broadening patient care options. "It is important not to separate treatment for depression from treatment for diabetes," he said. "Depression is associated with poor diabetes management. If management of diabetes is stressful, people may not follow guidelines.
We need to look at the whole picture, what are the mental problems, physical problems, and try to find an integrated treatment approach to those with symptoms of depression." "Research has shown that integrated treatment is more effective and better at focusing on the individual," Schmitz added. "But this approach is a recent development and integrated treatments are not widely available." Dr. Roger McIntyre, a professor of psychiatry and pharmacology at the University of Toronto who was not involved in the study, agreed diabetes patients should get early treatment with therapy for minor depression, while doctors also take a more holistic approach towards treating diabetes, including helping patients improve their quality of life and ability to care for themselves. "This obviously requires an intensive resource-heavy approach," McIntyre said. "And the reality is that these resources are not available and patients need to be self managers and need to work in partnership with providers."
The disease affects 25.8 million people in the U.S. and that number is expected to rise dramatically during the next 20 years, according to the Centers for Disease Control and Prevention. Type 2 diabetes is often associated with obesity, but the elderly are also at high risk, with an estimated 27 percent of the over-65 population suffering from the disease. Past research has found that nearly one-fifth of type-2 diabetics in the U.S. experience major depression, which is almost twice the rate seen in the general population. Some studies also link the combination of type 2 diabetes and depression with difficulty managing blood sugar levels and other health complications as well as increased risk of death.
read for more details visit my web page http://www.dailystrength.org/people/3658851/journal/8578893
Most research to date has focused on the role of major depression in poor health outcomes for diabetes patients, but Schmitz and his colleagues wanted to know if mild depression symptoms carried the same risks. For their study, published in Diabetes Care, the researchers followed 1,064 adults, aged 18 to 80 years old, from the larger Montreal Diabetes and Well Being Study for five years. The participants received a battery of surveys that assessed symptoms of depression, measures of disability, quality of life, diabetes-related health complications, social background, exercise and medical and psychiatric history, particularly related to treatment for depression. here is another about link http://www.kiwibox.com/camillafrank/blog/entry/112211095/you-should-not-abandon-active-recreation-outdoors/?pPage=0
The study team defined depression by a score based on symptoms experienced over a period of two weeks. While major depression would require at least five out of nine symptoms - such as appetite changes, fatigue and suicidal thinking - persisting over that time, mild depression would constitute fewer than five symptoms experienced at least once over the previous two weeks. The researchers also looked at health-related quality of life, based on the individuals' own perceptions of how burdensome their health problems were, and translated into a number of "unhealthy days" the person reported over the past month. They found that as the number of episodes of mild depression increased, the risk of impaired health and quality of life grew as well. For participants with one minor depression episode, the rate of poor functioning in daily activities such as work,
domestic responsibilities and self-care was 50 percent higher compared to those who had no depression. For patients with four or more bouts of mild depression, the risk of poor functioning was almost 300 percent greater and the risk of impaired health-related quality of life was nearly 250 percent greater than for those without depression. Schmitz told Reuters Health the study points to the need for broadening patient care options. "It is important not to separate treatment for depression from treatment for diabetes," he said. "Depression is associated with poor diabetes management. If management of diabetes is stressful, people may not follow guidelines.
We need to look at the whole picture, what are the mental problems, physical problems, and try to find an integrated treatment approach to those with symptoms of depression." "Research has shown that integrated treatment is more effective and better at focusing on the individual," Schmitz added. "But this approach is a recent development and integrated treatments are not widely available." Dr. Roger McIntyre, a professor of psychiatry and pharmacology at the University of Toronto who was not involved in the study, agreed diabetes patients should get early treatment with therapy for minor depression, while doctors also take a more holistic approach towards treating diabetes, including helping patients improve their quality of life and ability to care for themselves. "This obviously requires an intensive resource-heavy approach," McIntyre said. "And the reality is that these resources are not available and patients need to be self managers and need to work in partnership with providers."
New Diabetes Drug OKd by FDA Panel
A new blazon of diabetes biologic from Bristol-Myers Squibb and AstraZeneca has been accustomed by U.S. medical experts, two years afterwards it was alone by regulators because of assurance concerns.By a askew vote of 13 to 1, the advising console to the U.S. Food and Biologic Administration voted on Thursday to acclaim approval of dapagliflozin and said the allowances of the anesthetic appeared to outweigh its risks.The FDA about follows the admonition of its advising panels, but is beneath no obligation to do so.In addition vote, by 10 to 4, the console begin the biologic appeared to accept a favorable cardiovascular assurance profile.The FDA alone the anesthetic in January 2012 afterwards a antecedent medical advising console said analytic abstracts did not accommodate abundant authoritativeness about its blight and affection risks.The latest console accommodation is accordingly a abatement for the two drugmakers and will advice consolidate analyst forecasts for the medicine. article research by
http://lifestyle.keepsblogging.com/
That is decidedly acceptable for AstraZeneca, which is disturbing with a attenuate activity of new drugs and appear alloyed after-effects with a new gout biologic on Friday. Andrew Baum, an analyst at Citi, said FDA approval of dapagliflozin would additionally accessible the aperture for fixed-dose combinations of the biologic with the earlier anesthetic metformin, as able-bodied as potentially with Bristol and AstraZeneca's Onglyza.The new drug, which is already awash in Europe beneath the cast name Forxiga, blocks SGLT2, a protein that works apart of insulin to lower claret sugar. By blocking the branch from reabsorbing claret sugar, for more details go to the link http://fortalent.com/blog/view/s/2013-12-19-alternating-contraction-and-relaxation-of-the-pelvic-muscles/
the biologic spurs abatement of glucose through the urine.Johnson & Johnson afresh won approval for a battling SGLT2 biologic alleged Invokana, or canagliflozin, sales of which accept been decidedly strong, underlining the bartering abeyant of the biologic class.Invokana afflicted action in one ample balloon by authoritative claret amoroso bigger than Merck & Co's Januvia, a blockbuster biologic that belongs to a altered and almost new chic of diabetes treatments alleged DPP4 inhibitors.Analysts, on average, anticipation accepted sales of $806 actor for dapagliflozin in 2019, according to accord estimates aggregate by Thomson Reuters Pharma.CANCER DISCUSSIONSome associates of the go to for about health
http://starbar.co.za/groups/topic/view/group_id/49/topic_id/11/post_id/11
FDA advising panel, in a day-long affair on Thursday, bidding affair that 10 patients demography dapagliflozin in a ample balloon were afterwards diagnosed with float cancer. But added console associates said six of those cases occurred aural months afterwards analysis began, and were accordingly apparently not accompanying to the biologic because the blight about takes years to develop. Others acclaimed that the all-embracing accident of all cancers in patients demography dapaglifozin was agnate to the all-embracing accident apparent in patients who accustomed placebos."I don't anticipate we can abolish it," apropos to the float blight risk, said console affiliate
Dr. Milton Packer, a cardiologist and administrator of analytic sciences with the University of Texas Southwestern Medical Center in Dallas.Packer said he was counting on the FDA to crave the accessible float accident to be included in the drug's amalgamation admit label."I absolutely absolutely like this drug," Packer said, acquainted that the diabetes biologic lowers claret burden and causes weight loss, clashing abounding diabetes drugs that account weight gain.Bristol-Myers and AstraZeneca in July resubmitted their U.S. business appliance for dapaglifozin for analysis of adults with blazon 2 diabetes, the best accepted anatomy of diabetes that is awful affiliated to obesity.The revised appliance included abstracts from several new studies and added abiding abstracts from studies ahead submitted to the FDA.
http://lifestyle.keepsblogging.com/
That is decidedly acceptable for AstraZeneca, which is disturbing with a attenuate activity of new drugs and appear alloyed after-effects with a new gout biologic on Friday. Andrew Baum, an analyst at Citi, said FDA approval of dapagliflozin would additionally accessible the aperture for fixed-dose combinations of the biologic with the earlier anesthetic metformin, as able-bodied as potentially with Bristol and AstraZeneca's Onglyza.The new drug, which is already awash in Europe beneath the cast name Forxiga, blocks SGLT2, a protein that works apart of insulin to lower claret sugar. By blocking the branch from reabsorbing claret sugar, for more details go to the link http://fortalent.com/blog/view/s/2013-12-19-alternating-contraction-and-relaxation-of-the-pelvic-muscles/
the biologic spurs abatement of glucose through the urine.Johnson & Johnson afresh won approval for a battling SGLT2 biologic alleged Invokana, or canagliflozin, sales of which accept been decidedly strong, underlining the bartering abeyant of the biologic class.Invokana afflicted action in one ample balloon by authoritative claret amoroso bigger than Merck & Co's Januvia, a blockbuster biologic that belongs to a altered and almost new chic of diabetes treatments alleged DPP4 inhibitors.Analysts, on average, anticipation accepted sales of $806 actor for dapagliflozin in 2019, according to accord estimates aggregate by Thomson Reuters Pharma.CANCER DISCUSSIONSome associates of the go to for about health
http://starbar.co.za/groups/topic/view/group_id/49/topic_id/11/post_id/11
FDA advising panel, in a day-long affair on Thursday, bidding affair that 10 patients demography dapagliflozin in a ample balloon were afterwards diagnosed with float cancer. But added console associates said six of those cases occurred aural months afterwards analysis began, and were accordingly apparently not accompanying to the biologic because the blight about takes years to develop. Others acclaimed that the all-embracing accident of all cancers in patients demography dapaglifozin was agnate to the all-embracing accident apparent in patients who accustomed placebos."I don't anticipate we can abolish it," apropos to the float blight risk, said console affiliate
Dr. Milton Packer, a cardiologist and administrator of analytic sciences with the University of Texas Southwestern Medical Center in Dallas.Packer said he was counting on the FDA to crave the accessible float accident to be included in the drug's amalgamation admit label."I absolutely absolutely like this drug," Packer said, acquainted that the diabetes biologic lowers claret burden and causes weight loss, clashing abounding diabetes drugs that account weight gain.Bristol-Myers and AstraZeneca in July resubmitted their U.S. business appliance for dapaglifozin for analysis of adults with blazon 2 diabetes, the best accepted anatomy of diabetes that is awful affiliated to obesity.The revised appliance included abstracts from several new studies and added abiding abstracts from studies ahead submitted to the FDA.
Gum Disease Treatment Doesn't Improve Diabetes: Study
Typical, nonsurgical treatment of gum disease in people with type 2 diabetes will not improve their blood-sugar control, a new study suggests.
There's long been a connection between gum disease and wider health issues, and experts say a prior study had offered some evidence that treatment of gum disease might enhance blood-sugar control in patients with diabetes. for more information about health
http://pregnancy.isintofashion.com/
ALERT: Reverse Type 2 Diabetes. New Strategies Show How.
Nearly half of Americans over age 30 are believed to have gum disease, and people with diabetes are at greater risk for the problem, the researchers said. Well-controlled diabetes is associated with less severe gum disease and a lower risk for progression of gum disease, according to background information in the study.
But would an easing of gum disease help control patients' diabetes? To find out, the researchers, led by Steven Engebretson of New York University, tracked outcomes for more than 500 diabetes patients with gum disease who were divided into two groups.
One group's gum disease was treated using scaling, root planing and an oral rinse, followed by further gum disease treatment after three and six months. here is another about link http://healthylife.fashionistblog.com/
The other group received no treatment for their gum disease. Scaling and root planing involves scraping away the tartar from above and below the gum line, and smoothing out rough spots on the tooth's root, where germs can collect, according to the U.S. National Institutes of Health. After six months, people in the treatment group showed improvement in their gum disease. There was no difference, however, in blood-sugar control between the two groups, according to the findings, which were published in the Dec. 18 issue of the Journal of the American Medical Association. read for more details visit my web page
http://fitnesshelps.stylelists.net/
These findings do not support the use of nonsurgical gum disease treatment to improve blood-sugar control in people with diabetes, the researchers said. Experts said the finding was in line with what is known on the subject. "The results don't surprise me," said Dr. Gerald Bernstein, director of the Diabetes Education Program at Beth Israel Medical Center in New York City. "[Gum disease] requires physical intervention to remove offending plaques and microinfection that does not easily clear with brushing and rinsing." What is really important is how inflammation linked to gum disease is related to wider cardiac inflammation, Bernstein said.
That relationship might influence the rate at which artery-hardening plaques are deposited in blood vessels. Dr. Spyros Mezitis, an endocrinologist at Lenox Hill Hospital in New York City, said it's well known that gum disease is "associated with worsening of [blood-sugar] control in diabetics." But the current study suggests that "[gum] treatment improves the common disease and preserves teeth but should not be used to control diabetes," he said. "Larger studies are needed to confirm these findings," Mezitis added.
http://pregnancy.isintofashion.com/
The other group received no treatment for their gum disease. Scaling and root planing involves scraping away the tartar from above and below the gum line, and smoothing out rough spots on the tooth's root, where germs can collect, according to the U.S. National Institutes of Health. After six months, people in the treatment group showed improvement in their gum disease. There was no difference, however, in blood-sugar control between the two groups, according to the findings, which were published in the Dec. 18 issue of the Journal of the American Medical Association. read for more details visit my web page
http://fitnesshelps.stylelists.net/
These findings do not support the use of nonsurgical gum disease treatment to improve blood-sugar control in people with diabetes, the researchers said. Experts said the finding was in line with what is known on the subject. "The results don't surprise me," said Dr. Gerald Bernstein, director of the Diabetes Education Program at Beth Israel Medical Center in New York City. "[Gum disease] requires physical intervention to remove offending plaques and microinfection that does not easily clear with brushing and rinsing." What is really important is how inflammation linked to gum disease is related to wider cardiac inflammation, Bernstein said.
That relationship might influence the rate at which artery-hardening plaques are deposited in blood vessels. Dr. Spyros Mezitis, an endocrinologist at Lenox Hill Hospital in New York City, said it's well known that gum disease is "associated with worsening of [blood-sugar] control in diabetics." But the current study suggests that "[gum] treatment improves the common disease and preserves teeth but should not be used to control diabetes," he said. "Larger studies are needed to confirm these findings," Mezitis added.
Dyslexia Caused by Faulty Brain Wiring: Study
A roadblock in the brain makes reading difficult for people with dyslexia, a new study suggested Thursday, contradicting long-held opinion.
The findings in the U.S. journal Science add to an ongoing debate over whether the inherited neurological disorder is caused by faulty brain wiring or the brain's inability to understand the interaction of sounds and symbols that form language.
Dyslexia is a learning disability that affects about 10 percent of the population and occurs among people of all economic and ethnic backgrounds. for more information about health http://effectivetreatments.biglaunch.net/
The findings were based on brain scans of 23 people with dyslexia and 22 without, showing dyslexics understand the sound units fine but lack the brain connections to process them. "Quite to our surprise, and probably to the surprise of the broader dyslexia field, we found that phonetic representations are perfectly intact in adults with dyslexia," said researcher Bart Boets, a professor of psychiatry at the University of Leuven in Belgium. Boets said his team's research counters the predominantly held opinion that somehow people with dyslexia have an inferior ability to recognize go to for about health http://reviewlity.impressivefood.com/
the distinct sounds of language. Instead, they found impaired connections between the right and left auditory regions, where phonetic representations are processed, and Broca's region, where higher level phonological processing takes place. "Our findings indicate that the speech sound representations themselves are intact, but a dysfunctional connection between frontal and temporal language areas impedes efficient access to the representations," said Boets. Study subjects listened to a sequence of four partial words, followed by another sequence in which a consonant or vowel had been switched, such as ba-ba-ba-ba, da-da-da-da. Then they were asked to identify what had changed. The team used advanced functional magnetic resonance imaging (fMRI) techniques to measure the unique fingerprint of each sound in the brain, and found the quality of impressions was the same in normal readers and dyslexic people.
In other words, their brains were identifying the sounds and their changes just like normal readers. However, the dyslexic people took 50 percent longer to make their responses, according to Science. Researcher Hans Op de Beeck likened the experiment to having his daughter call from the landline telephone at their house to say she was home from school. That, he could verify, but what was she doing at home? Was she doing her homework or playing a game? He could not know for sure. read for more details visit my web page
http://healthcare.restaurantpages.net/
With this experiment, researchers were able to see that "the regions containing phonetic representations in adult dyslexic readers are doing their homework, that's for sure." Boets said he hopes the research could lead to better ways of improving the brain circuitry, perhaps through noninvasive brain stimulation techniques. However, the findings were questioned by neuroscientist Michael Merzenich at the University of California, San Francisco. Decades of "very extensive and compelling" evidence show that people with dyslexia process phonetic representations with lower fidelity than normal, he was quoted as telling Science. "You can't just ignore this literature," he said. The study was co-authored by experts at University College London, University of Oxford and ETH Zurich University in Switzerland.
The findings were based on brain scans of 23 people with dyslexia and 22 without, showing dyslexics understand the sound units fine but lack the brain connections to process them. "Quite to our surprise, and probably to the surprise of the broader dyslexia field, we found that phonetic representations are perfectly intact in adults with dyslexia," said researcher Bart Boets, a professor of psychiatry at the University of Leuven in Belgium. Boets said his team's research counters the predominantly held opinion that somehow people with dyslexia have an inferior ability to recognize go to for about health http://reviewlity.impressivefood.com/
the distinct sounds of language. Instead, they found impaired connections between the right and left auditory regions, where phonetic representations are processed, and Broca's region, where higher level phonological processing takes place. "Our findings indicate that the speech sound representations themselves are intact, but a dysfunctional connection between frontal and temporal language areas impedes efficient access to the representations," said Boets. Study subjects listened to a sequence of four partial words, followed by another sequence in which a consonant or vowel had been switched, such as ba-ba-ba-ba, da-da-da-da. Then they were asked to identify what had changed. The team used advanced functional magnetic resonance imaging (fMRI) techniques to measure the unique fingerprint of each sound in the brain, and found the quality of impressions was the same in normal readers and dyslexic people.
In other words, their brains were identifying the sounds and their changes just like normal readers. However, the dyslexic people took 50 percent longer to make their responses, according to Science. Researcher Hans Op de Beeck likened the experiment to having his daughter call from the landline telephone at their house to say she was home from school. That, he could verify, but what was she doing at home? Was she doing her homework or playing a game? He could not know for sure. read for more details visit my web page
http://healthcare.restaurantpages.net/
With this experiment, researchers were able to see that "the regions containing phonetic representations in adult dyslexic readers are doing their homework, that's for sure." Boets said he hopes the research could lead to better ways of improving the brain circuitry, perhaps through noninvasive brain stimulation techniques. However, the findings were questioned by neuroscientist Michael Merzenich at the University of California, San Francisco. Decades of "very extensive and compelling" evidence show that people with dyslexia process phonetic representations with lower fidelity than normal, he was quoted as telling Science. "You can't just ignore this literature," he said. The study was co-authored by experts at University College London, University of Oxford and ETH Zurich University in Switzerland.
3 Foods Linked With Depression
The holidays aren't only a time of good cheer and celebration. For many Americans, they are accompanied by depression and weight gain. New research suggests that may not just be coincidental.
Special: The Healing Powers of Vinegar: Arthritis, Heart, Brain, More
Many of the foods we eat over the holiday season and other times of the year — because we are rushed and may not make time for healthier meals — are linked with depression, according to a new report on the LiveScience http://articles.al.lv/article.php?id=246628
Website. Fast Food: People who eat fast food — such as commercial baked goods, hamburgers, hot dogs, and pizza — are 51 percent more likely to develop depression than those who don't, according to a 2012 study in the journal Public Health Nutrition. Refined grains: Pasta, white rice, and bagels are all foods made with refined grains that have been identified as inflammatory and linked to depression, particularly in women over 50, according to an October 2013 study in the journal Brain, Behavior and Immunity. for more information about health http://tinnitusmiracle.pagelanding.net/
The study tracked the eating habits of more than 40,000 women and found that those who consumed such foods regularly were more likely to suffer from depression. Soft drinks: Grabbing a cola while shopping or on the run may give you a quick pick-me-up, but the same study in Brain, Behavior and Immunity found women who consume soft drinks as part of their regular diets also experience higher rates of depression. Health experts note that a small portion of any one food is unlikely to raise depression risk, so an occasional bowl of pasta, soft drink, or fast food burger is no cause for concern. But if such foods are regular stapes of your diet, you might want to make some changes.
Website. Fast Food: People who eat fast food — such as commercial baked goods, hamburgers, hot dogs, and pizza — are 51 percent more likely to develop depression than those who don't, according to a 2012 study in the journal Public Health Nutrition. Refined grains: Pasta, white rice, and bagels are all foods made with refined grains that have been identified as inflammatory and linked to depression, particularly in women over 50, according to an October 2013 study in the journal Brain, Behavior and Immunity. for more information about health http://tinnitusmiracle.pagelanding.net/
The study tracked the eating habits of more than 40,000 women and found that those who consumed such foods regularly were more likely to suffer from depression. Soft drinks: Grabbing a cola while shopping or on the run may give you a quick pick-me-up, but the same study in Brain, Behavior and Immunity found women who consume soft drinks as part of their regular diets also experience higher rates of depression. Health experts note that a small portion of any one food is unlikely to raise depression risk, so an occasional bowl of pasta, soft drink, or fast food burger is no cause for concern. But if such foods are regular stapes of your diet, you might want to make some changes.
Subscribe to:
Comments (Atom)